Valuation: Mabion S.A.

Market Cap 129M 32.61M 29.26M 27.05M 24.5M 45.77M 3.11B 46.32M 323M 1.63B 122M 120M 5.16B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 135M 34.21M 30.69M 28.38M 25.7M 48.01M 3.26B 48.59M 339M 1.7B 128M 126M 5.41B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
71.02%
Yield 2024 *
-
Yield 2025 -
1 week-2.80%
Current month+1.40%
1 month+3.51%
3 months+7.70%
6 months+2.57%
Current year+14.18%
1 week 7.83
Extreme 7.83
8.48
1 month 7.64
Extreme 7.64
8.48
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
81.7
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 23/02/2021
Chairman 60 13/05/2021
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.80%-5.34%-53.50% 32.64M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.06%-0.05%+26.75%+56.06% 44.75B
+2.41%-3.27%+17.98%+100.33% 41.62B
+0.69%-3.76%+221.42%+918.91% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.99%-0.38%+45.97%+140.35% 38.05B
Weighted average by Cap. +3.11%-0.29%+47.11%+160.55%

Financials

2024 2025
Net sales 69.02 17.47 15.68 14.49 13.13 24.52 1.66K 24.82 173.28 870.75 65.56 64.18 2.76K 15.76 3.99 3.58 3.31 3 5.6 379.9 5.67 39.56 198.79 14.97 14.65 631.09
Net income -6.33M -1.6M -1.44M -1.33M -1.2M -2.25M -153M -2.28M -15.9M -79.91M -6.02M -5.89M -254M -62.61M -15.85M -14.22M -13.15M -11.91M -22.25M -1.51B -22.52M -157M -790M -59.48M -58.23M -2.51B
Net Debt -35.18M -8.91M -7.99M -7.39M -6.69M -12.5M -848M -12.65M -88.34M -444M -33.42M -32.72M -1.41B 6.32M 1.6M 1.43M 1.33M 1.2M 2.24M 152M 2.27M 15.86M 79.68M 6M 5.87M 253M
Projected Income Statement - Annual - Mabion S.A.
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
28/10/26 PLN 7.970 0.00% 16,644
27/10/26 PLN 7.970 -0.38% 14,906
26/10/26 PLN 8.000 -0.37% 23,487
23/10/26 PLN 8.030 -3.49% 33,841
22/10/26 PLN 8.320 +1.46% 83,725

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Mabion S.A.